Precision Bio wants to show there's a better way to edit genes — and now it has $126M in IPO cash to prove it
After spending the second half of last year laying the carpet for an IPO — complete with a crossover round and a big partnership with Gilead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
